Cargando…
The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
COVID-19 convalescent plasma (CCP) is widely used as a treatment. Although there are sufficient safety data, high-level evidence of efficacy is still lacking. We summarize here the results from randomized controlled trials (RCTs) published to date and analyze their flaws and biases. We then provide...
Autores principales: | Focosi, Daniele, Farrugia, Albert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836915/ https://www.ncbi.nlm.nih.gov/pubmed/33130197 http://dx.doi.org/10.1016/j.ijid.2020.10.074 |
Ejemplares similares
-
Convalescent Plasma Therapy for COVID-19: State of the Art
por: Focosi, Daniele, et al.
Publicado: (2020) -
Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022) -
The Assessment of Convalescent Plasma Efficacy against COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2020) -
Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews
por: Franchini, Massimo, et al.
Publicado: (2021) -
Heterogeneity in COVID‐19 Convalescent Plasma Clinical Trials
por: Müller‐Olling, Mirco, et al.
Publicado: (2021)